Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | TACR1 | P25103 | 9/20 | 0.55 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.54 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.54 |
| ▸ | MLYCD | O95822 | 1/20 | 0.52 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.49 |
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16127840 | 0.84 | KMT2A (0.65) | TACR1P2RX1TMPRSS4MLYCDKMT2A | |
| SCHEMBL5364748 | 0.83 | HPGD (0.78) | CA1CA2LMNAHPGDGAA | |
| SCHEMBL6866336 | 0.81 | CHRNB2 (0.68) | GAATACR1P2RX1TMPRSS4KMT2A | |
| SCHEMBL16088678 | 0.80 | P2RX1 (0.57) | LMNAHPGDTACR1P2RX1TMPRSS4 | |
| SCHEMBL7199403 | 0.79 | MT-CO2 (0.63) | TACR1P2RX1TMPRSS4MLYCD | |
| SCHEMBL22114105 | 0.78 | TACR1 (0.55) | LMNAHPGDTACR1P2RX1TMPRSS4 | |
| SCHEMBL16128007 | 0.78 | P2RX1 (0.55) | LMNAHPGDTACR1P2RX1TMPRSS4 | |
| SCHEMBL5740118 | 0.78 | TACR1 (0.69) | TACR1KMT2A | |
| SCHEMBL23864576 | 0.76 | KMT2A (0.66) | LMNAHPGDGAAL3MBTL1MLYCD | |
| SCHEMBL6862802 | 0.76 | TACR1 (0.61) | LMNAHPGDGAATACR1P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1157006-B1 | PHENYL- AND PYRIDINYL DERIVATIVES AS NEUROKININ 1 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2006-10-25 | — | — | EP | disclosed |
| CN-1131212-C | Phenyl-and pyridinyl derivatives | HOFFMANN LA ROCHE (CH) | 2003-12-17 | — | — | CN | disclosed |
| US-6596773-B2 | Central nervous system disorders | HOFFMANN-LA ROCHE INC. | 2003-07-22 | — | — | US | disclosed |
| US-20020111367-A1 | Phenyl substituted pyridine and benzene derivatives | BOS MICHAEL (CA) | 2002-08-15 | — | — | US | disclosed |
| US-6407111-B1 | SUBSTANCE P OR NEUROKININ 1 ANTAGONISTS; ANTIINFLAMMATORY, ANTIDEPRESSANT, ANTIARTHRITIC, AND ANTIASTHMATIC AGENTS; PARKINSON*S DISEASE, INFLAMMATORY BOWEL DISEASE, CENTRAL NERVOUS SYSTEM AND RHEUMATIC DISORDERS | HOFFMANN-LA ROCHE INC. | 2002-06-18 | — | — | US | disclosed |
| CN-1341101-A | Phenyl-and pyridinyl derivatives | HOFFMANN LA ROCHE (CH) | 2002-03-20 | — | — | CN | disclosed |
| EP-1157006-A2 | PHENYL- AND PYRIDINYL DERIVATIVES AS NEUROKININ 1 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000050398-A2 | PHENYL- AND PYRIDINYL DERIVATIVES AS NEUROKININ 1 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111367-A1 | Phenyl substituted pyridine and benzene derivatives | BDKRB1, BAK1, PBK | CA1 4212/4885CA2 2410/4885LMNA 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.